4-Hydroxyphenethyl alcohol (tyrosol, CAS 501-94-0, molecular weight 138.16 g/mol) is a monophenolic phenylethanoid supplied as a white to off-white crystalline powder. The pharmaceutical grade is available under two product models: TYR-PG-OS for tablet, capsule, and granule manufacturing, and TYR-PG-INJ for sterile oral and parenteral compounding. The OS grade is controlled for particle-size distribution, bulk density, and flowability to support direct compression and dry or wet granulation; the INJ grade is filtered through a validated 0.2 µm membrane, tested for pyrogens, and released against injectable specifications. Both grades are manufactured under current good manufacturing practice and are supported by a certificate of analysis covering assay, related substances, residual solvents, water content, residue on ignition, and microbial enumeration.

The product is routinely specified at not less than 98.0% and not more than 102.0% assay on the dried basis by high-performance liquid chromatography. Total related substances are controlled to not more than 0.5% w/w for the OS grade and not more than 0.2% w/w for the INJ grade; any unspecified impurity is limited to not more than 0.10% w/w. Water content is determined according to USP <921> or Ph. Eur. 2.2.32, with a limit of not more than 1.0% m/m for the OS grade and not more than 0.5% m/m for the INJ grade. Residue on ignition is limited to not more than 0.1% m/m by USP <281> or Ph. Eur. 2.4.16. The representative release specifications are summarized below.

What oxidative and light-induced degradation pathways must be controlled during tyrosol processing?

Tyrosol contains a para-hydroxyl group that can undergo oxidative coupling and ionization to a phenolate species under oxygen and visible light. The reaction is accelerated by transition-metal ions such as iron(III) and copper(II), and by alkaline pH. Processing controls therefore include nitrogen blanketing, amber glass or aluminium-laminated packaging, and exclusion of unprotected steel contact surfaces. A critical threshold exists at pH above 7.0: the ionized phenolate form reacts more rapidly with dissolved oxygen in aqueous media. For injectable manufacturing, aqueous solutions are buffered to pH 4.0–5.0 with citrate or acetate buffer, with pH monitored according to USP <791>. Dissolved oxygen is reduced by nitrogen sparging before filling, and headspace oxygen is held below ambient oxygen partial pressure. Forced-degradation studies at 60°C and 75% RH are used to identify oxidative by-products; published forced-degradation data specific to pharmaceutical-grade tyrosol are limited, but the general phenolic oxidation route is well documented.

Direct compression formulations containing tyrosol are prepared by blending the OS grade with microcrystalline cellulose, mannitol, or dibasic calcium phosphate dihydrate in a diffusion mixer. The particle-size acceptance window is critical: high fine content increases cohesion and reduces bulk density, while an API D90 exceeding the filler D90 by more than 100 µm can produce segregation under low-shear transfer. Powder flow is measured by USP <1174> or Ph. Eur. 2.9.36; bulk density and tapped density are determined by USP <616> or Ph. Eur. 2.9.34. A batch with flow function coefficient below 4 is not suitable for direct compression and is redirected to granulation. During direct compression on a rotary tablet press, compression force is adjusted to achieve a tablet hardness of 50–90 N and friability not more than 1.0%. Tablets are accepted only when the weight relative standard deviation remains below 2.0% over a continuous run and when no sticking or picking is observed on the punch faces.

Injectable-Grade Bioburden, Endotoxin, and Subvisible Particle Limits

The INJ grade is released with a low bioburden specification before terminal preparation. Bacterial endotoxins are controlled according to USP <85> or Ph. Eur. 2.6.14; the limit is calculated from the maximum clinical dose using the formula K/M, where K is 5.0 EU/kg for a general parenteral preparation and M is the maximum dose in mg/kg/h. For a product intended for a 10 mg/kg/h infusion rate, the endotoxin limit is 0.5 EU/mg; release limits are set lower because subsequent processing can introduce pyrogens. Subvisible particulate matter is tested by light obscuration or microscopy according to USP <788> for larger-volume parenterals and Ph. Eur. 2.9.19. Acceptance criteria are not more than 25 particles ≥10 µm per mL and not more than 3 particles ≥25 µm per mL; for small-volume injectables, USP <787> is applied to pooled units. Sterility is confirmed by membrane filtration according to USP <71> or Ph. Eur. 2.6.1. Because tyrosol is not antibacterial at formulation concentrations, standard growth-promotion test organisms are used without neutralization steps.

Oral and injectable liquid formulations containing tyrosol require protection from headspace oxygen and trace metals. The active pharmaceutical ingredient is dissolved in water for injection, purified water, or a mixed aqueous/organic vehicle. Since tyrosol is a weak phenolic acid, pH is maintained below 7.0 to limit phenolate formation. Chelating agents such as disodium edetate are used at concentrations not exceeding 0.01% w/w in injectable formulations to sequester iron and copper ions; higher concentrations are avoided because of calcium-binding risk. Nitrogen sparging is applied to bulk solutions before filling, and sparging is stopped before filling to avoid aerosol entrainment. If terminal sterilization is performed, the thermal cycle is 121°C for 15 minutes with a validated F₀ value of not less than 12 minutes. For heat-sensitive formulations, aseptic filtration through a 0.22 µm sterilizing-grade filter is used instead of terminal heat treatment. Osmolality is adjusted with sodium chloride to 285–310 mOsm/kg and checked by USP <785>.

When Low-Bulk-Density Tyrosol Batches Move from Direct Compression to Dry Granulation

Batches with bulk density below 0.35 g/mL and flow function coefficient below 4 are converted to granules by roller compaction. Dry granulation is not a simple size-enlargement operation; it creates a discontinuous particle-size distribution and can generate a segregation-prone fraction if mill screens are selected without reference to ribbon thickness. Ribbon solid fraction is the primary control variable. For phenolic APIs with low bulk density, a ribbon solid fraction of 0.60–0.75 is targeted, and envelope density is measured to avoid through-porosity exceeding 25%. Milling through a 1.0 mm screen with a rotor speed of 40–60 rpm produces granule D50 between 150 and 300 µm. If granules are overmilled, fines content above 30% by sieve fraction reintroduces flow problems. Published data for this specific configuration are limited; therefore, process qualification should rely on ribbon-density response surfaces rather than on fixed roll-gap alone.

Granulated tyrosol can be compacted on a rotary tablet press at compression force of 10–20 kN with precompression force of 2–5 kN. Hardness is maintained at 50–90 N, and friability is kept below 1.0%. Capsule filling requires dosator or tamping-pin equipment; because tyrosol granules have low cohesiveness, fill weight relative standard deviation is maintained below 2.0% at a production rate of 60,000 capsules/h. If the granulation moisture exceeds 2.0% w/w after drying, compression is unstable due to sticking and picking; drying is repeated with reduced air humidity. The process window is therefore narrow at the drying endpoint and around the milling step.

Residual Solvent and Elemental Impurity Profiles under ICH Q3C and ICH Q3D

Residual solvents are controlled to the options in ICH Q3C. Class 1 solvents such as benzene and 1,2-dichloroethane are not used in the synthesis and must be absent at the level of detection; if detected, benzene is limited to 2 ppm and 1,2-dichloroethane to 5 ppm according to ICH Q3C Table 1. Class 2 solvents, if used in recrystallization or purification, are limited to the concentrations listed in Table 2 of the guidance; representative limits include methanol 3000 ppm, acetonitrile 410 ppm, dichloromethane 600 ppm, and toluene 890 ppm. Class 3 solvents such as acetone, ethanol, ethyl acetate, and isopropanol are limited to 5000 ppm or 50 mg/day, whichever is lower. The injectable grade adds the requirement that no residual organic solvent exceeds parenteral administration limits; terminal sterilization does not remove residual solvents, so control is achieved before drying and packaging.

Elemental impurities are controlled according to ICH Q3D and measured by inductively coupled plasma mass spectrometry after closed-vessel microwave digestion using USP <233>. The parenteral permitted daily exposures of lead, cadmium, arsenic, and mercury are 5, 2, 15, and 3 µg/day respectively; the oral grade uses the same lead and arsenic values but permits cadmium at 5 µg/day and mercury at 30 µg/day. Because the INJ grade is intended for injectable products, it applies the parenteral PDEs and reports the remaining ICH Q3D elements as below limit of quantitation unless the route-specific risk assessment indicates otherwise.

A Direct Comparison with Technical-Grade Tyrosol and Hydroxytyrosol Catechol APIs

Unlike technical-grade tyrosol used as a cosmetic or food intermediate, the pharma grade is not characterized only by a melting range or a simple UV assay. Technical material may contain more than 2.0% of unknown phenolics and may carry no endotoxin or particulate release; such material is not suitable for sterile injection or direct compression because the higher impurity burden can alter blend flow, tablet surface, and oxidative stability. The pharma-grade product therefore requires process validation, batch-to-batch impurity trending, and stability data under ICH Q1A conditions. Technical-grade tyrosol also frequently contains residual process solvents that are not controlled to ICH Q3C levels; these solvents can compromise tablet compressibility and cannot be accepted in injectable manufacture.

Compared with hydroxytyrosol, which carries an additional ortho-hydroxyl group, tyrosol has lower antioxidant activity but is less susceptible to catechol oxidation. Hydroxytyrosol forms quinone chelates with iron(III) and darkens in aqueous alkaline media, while tyrosol remains relatively stable because it lacks the ortho-dihydroxy grouping. This structural difference explains why tyrosol is generally easier to formulate in pH-buffered injectable solutions without excessive antioxidant use; hydroxytyrosol may require stronger antioxidants and chelating agents to prevent color formation. However, tyrosol does not provide the same level of radical scavenging; the two compounds should not be interchanged on an equal-weight basis. The monophenolic structure also reduces the risk of oxidative by-products during wet granulation and terminal sterilization, but it does not eliminate the need for oxygen and light control.

The powder and granule handling behavior of tyrosol differs from that of highly water-soluble crystalline APIs because its compression profile is sensitive to particle-size distribution and residual moisture. If the material is over-dried below 0.3% residual water, electrostatic charging can increase and die filling may become erratic. If residual water exceeds 1.0% in the OS grade, tablet hardness can decline and friability can rise. These boundaries define the operational envelope for direct compression, dry granulation, and wet granulation and are part of the technical release specification rather than negotiable commercial claims.

Injection-grade tyrosol also differs from oral-grade tyrosol in particulate control, endotoxin limit, and container-closure compatibility. The INJ grade is released only after subvisible particulate testing, bacterial endotoxin testing, and sterility testing; the OS grade is not released against injectable particulate or endotoxin criteria. For aqueous injectable formulation, the active pharmaceutical ingredient should be dissolved in water for injection under low-oxygen conditions and filtered before filling. The formulation pH is adjusted after dissolution because dissolved carbon dioxide can shift the initial pH; adjustment is made with dilute hydrochloric acid or sodium hydroxide under continuous pH monitoring. The injectable solution should not be held for prolonged periods in unprotected stainless steel unless the vessel has been passivated and the solution is nitrogen-blanketed.

Batch-to-batch variability in residual solvent profile is a common bottleneck observed on production scale when the same crystallization solvent is recycled without adequate distillation control. In such cases, methanol or ethyl acetate can accumulate in the mother liquor and carry into the isolated API, producing release failures under ICH Q3C. Preventative control includes solvent recovery with specified boiling fractions, in-process gas chromatographic monitoring, and restricted solvent use during the final recrystallization of the INJ grade. For granulation, the main production bottleneck is not chemical degradation but flow control: a batch with acceptable assay and related substances can still fail direct compression if the particle-size distribution shifts into the cohesive fine range after milling. In this case, the batch is routed to dry granulation rather than discarded.

The product is therefore positioned as an integrated API for oral solid and sterile liquid manufacturing, not as a single-grade material with generic applicability. The OS grade is selected for tablet, capsule, and granule processes where flow, compressibility, and residual-solvent control are primary; the INJ grade is selected for injectable and sterile oral preparations where endotoxin, subvisible particulate matter, and elemental impurity control are primary. The two grades share the same molecular identity and assay performance but are not interchangeable in downstream release testing.